Leading Driver In The Phenobarbital Market 2025: Growth Of The Phenobarbital Market Due To Rising Seizure Cases Globally

June 19, 2025 06:34 PM AEST | By EIN Presswire
 Leading Driver In The Phenobarbital Market 2025: Growth Of The Phenobarbital Market Due To Rising Seizure Cases Globally
Image source: EIN Presswire

LONDON, GREATER LONDON, UNITED KINGDOM, June 19, 2025 /EINPresswire.com/ -- A key focus of the report is the robust growth of the phenobarbital market in recent years. The market valuation is expected to surge from $1.47 billion in 2024 to $1.55 billion in 2025, reflecting a compound annual growth rate CAGR of 5.4%. This growth is underpinned by several factors, including the widespread use of phenobarbital in epilepsy management, a rise in the prevalence of epilepsy and seizure disorders, government supply programs, an upswing in demand in veterinary applications, and efforts toward widespread health coverage.

What Is The Projected Future Growth Of The Phenobarbital Market Size?
Looking forward, the phenobarbital market is set to witness substantial expansion. The market cap is anticipated to reach $1.91 billion in 2029, with a CAGR of 5.2%. The market's growth in the forecast period is attributed to factors such as the proliferation of generic drug manufacturing, increasing focus on neurological disease management, the advancement of digital supply chains and e-pharmacy systems, regulatory changes favoring generic use, and stability in regulatory pathways for generics. The market is also expected to be influenced by major trends like development of easy-to-administer delivery forms, innovative R&D efforts, extended-release formulations, enhanced drug delivery systems,

Get Your Free Sample Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24377&type=smp

What Are The Key Drivers Propelling The Growth Of The Phenobarbital Market?
Epilepsy, a neurological disorder characterized by recurrent unprovoked seizures resulting from abnormal electrical activity in the brain, is becoming increasingly prevalent due to enhanced awareness leading to more people recognizing symptoms and seeking medical diagnosis. Phenobarbital, an anticonvulsant medication that works by slowing down the activity of the brain's neurons, is particularly effective in preventing and controlling seizures. The increase in epilepsy cases is expected to drive the phenobarbital market forward.

What Key Player Strategies Are Driving The Phenobarbital Market?
The report identifies the major companies operating in the phenobarbital market. These include F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Eli Lilly and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi AG, Sun Pharmaceutical Industries Ltd., Dr. Reddy’s Laboratories Ltd., Lupin Limited, H. Lundbeck A/S, Sandoz Group AG, Yashiro Pharmaceutical Co. Ltd., Hikma Pharmaceuticals PLC, Par Pharmaceutical Inc., Shandong Xinhua Pharmaceutical Co. Ltd., Manus Aktteva Biopharma LLP, JPN Pharma Pvt. Ltd., Alkaloida Chemical Company Zrt., and Harman Finochem Ltd.

Order Your Report Now For A Swift Delivery:
https://www.thebusinessresearchcompany.com/report/phenobarbital-global-market-report

What Are The Emerging Trends In The Phenobarbital Market?
Increasingly, companies in the phenobarbital market are striving to innovate and develop effective solutions such as phenobarbital sodium, which enhances the safety and effectiveness of treatments. For example, in January 2023, India-based Sun Pharmaceutical Industries Ltd launched SEZABY phenobarbital sodium in the U.S., the first and only FDA-approved medication specifically indicated for treating seizures in both term and preterm neonates.

How Is The Phenobarbital Market Segmented?
The phenobarbital market covered in this report is broken down by indication, dosage forms, distribution channels, applications, and by end users. Additionally, epilepsy is segmented into focal partial seizures, generalized tonic-clonic seizures, status epilepticus, refractory epilepsy, and idiopathic epilepsy, while neonatal seizures are broken down further into subsegments.

What Are The Regional Insights In The Phenobarbital Market?
In 2024, North America was found to be the largest region in the phenobarbital market, with Asia-Pacific predicted to be the fastest-growing region during the forecast period. The regions analyzed in the phenobarbital market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Browse Through More Similar Reports By The Business Research Company:
Asthma Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Artificial Intelligence (AI) In Drug Discovery Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/artificial-intelligence-in-drug-discovery-global-market-report

Atherosclerosis Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

About The Business Research Company
Learn More About The Business Research Company. With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Oliver Guirdham
The Business Research Company
+44 20 7193 0708
[email protected]
Visit us on social media:
LinkedIn
Facebook
X

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.